News
Stay up to date on topics that are important to Nurse Practitioners.
-
FDA Approves Topical Cream for Inflammatory Rosacea
The FDA approved benzoyl peroxide 5% cream (Epsolay) for adults with inflammatory lesions of rosacea. The medication uses…
-
Nonstimulant Approved for Adult ADHD
The FDA approved the use of viloxazine (Qelbree) extended-release capsules for adults 18 years of age and older…
-
FDA Warns of Risks Associated With Noninvasive Prenatal Screening Tests
The FDA is warning the public of the risk of false results, inappropriate use, and inappropriate interpretation of…
-
FDA Approves First Sublingual Medication for Agitation in Serious Mental Illness
The FDA approved dexmedetomidine (Igalmi) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar…
-
FDA Approves New Indication for IL-23 Inhibitor for Adults With Active Psoriatic Arthritis
Risankizumab-rzaa (Skyrizi) is now approved for the treatment of adults with active psoriatic arthritis. It is the only…
-
FDA Approves Treatment for Wider Range of Patients With Heart Failure
The FDA approved empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure in…
-
First Generic of Cyclosporine Ophthalmic Emulsion Eye Drops (Restasis) Approved for Dry Eye
The FDA approved the first generic version of cyclosporine ophthalmic emulsion 0.05% single-use vials (Restasis) to increase tear…
-
Rivaroxaban (Xarelto) Approved for Pediatric Indication to Help Prevent, Treat Clots
The FDA approved two new pediatric indications for rivaroxaban (Xarelto), a factor Xa anticoagulant with multiple indications in…
-
New Medication Spray Approved for Seasonal Allergic Rhinitis
The FDA approved olopatadine hydrochloride/mometasone furoate (Ryaltris) nasal spray, a combination histamine-1(H1)-receptor inhibitor/corticosteroid, for the treatment of symptoms…
-
New Biologic Drug Approved for Moderate to Severe Atopic Dermatitis
The FDA approved tralokinumab-ldrm (Adbry), a biologic for the treatment of moderate-to-severe atopic dermatitis in adults 18 years…
-
FDA Approves New Drug for Insomnia in Adults
The FDA has approved daridorexant (Quviviq) 25 mg and 50 mg for the treatment of adult patients with…
-
Vaginal Gel Approved for Bacterial Vaginosis
The FDA approved clindamycin phosphate vaginal gel, 2% (Xaciato), for the treatment of bacterial vaginosis in females 12…
Trending
-
FDA Approved Semaglutide Injection to Reduce Risk of Serious Heart Problems in Overweight Adults
-
The Role of Pharmacogenomics in Precision Mental Healthcare
-
OTC COVID-19 Diagnostic Tests May Have an Extended Shelf Life
-
AANP Offers Resources to Help NPs Detect and Treat Ulcerative Colitis
-
Multistate Outbreak of Salmonella Linked to Cucumbers
-
5 Key Benefits of Getting a Second Certification as a Nurse Practitioner
-
8 Key Tips for Effective Communication During Pediatric ENT Exams
-
Normalizing Anxiety: How NPs Can Guide Patients to Make Healthier Choices
-
CDC Endorses Lowering Pneumococcal Vaccination Age from 65 to 50
-
FDA Proposes Ban on Over-the-Counter Oral Nasal Congestion Medication
-
Using Technology to Combat Drug-Drug Interactions
-
Building a Strong Professional Nursing Network as a New Nurse Practitioner
Join our email list
Get new course alerts, newsletters and more delivered directly to your inbox
By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.